Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2020-07-14 AGM Information
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - French.pdf
AGM Information Classification · 90% confidence The document is a notification about the upcoming Annual General Meeting (AGM) for Medexus Pharmaceuticals Inc., including details such as the date of the meeting, registration dates for voting, and meeting location. It does not contain the AGM materials or presentations themselves, nor does it include financial data or results. The document is short (1272 characters) and serves as an announcement regarding the AGM logistics. Therefore, it fits best under AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related announcements about the AGM itself. Given the nature and length, confidence is high.
2020-07-14 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 95% confidence The document is a notice to Canadian Securities Regulatory Authorities regarding an upcoming Annual General Meeting (AGM) for Medexus Pharmaceuticals Inc. It provides details about the meeting date, record dates, meeting type, and proxy material distribution. The document is short (1121 characters) and serves as an announcement about the AGM rather than the AGM materials or minutes themselves. It does not contain financial data or detailed presentations. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related notices about the AGM.
2020-07-14 English
Annual MD&A - French.pdf
Regulatory Filings
2020-07-13 English
Audited annual financial statements – French.pdf
Regulatory Filings
2020-07-13 English
News release - English.pdf
Regulatory Filings
2020-07-09 English
News release - English.pdf
Annual Report Classification · 95% confidence The document is a detailed announcement of Medexus Pharmaceuticals' financial and operating results for the fourth quarter and fiscal year ended March 31, 2020. It includes comprehensive financial data such as revenue, gross profit, adjusted EBITDA, net loss, and operational highlights. The text also references the fiscal year and quarter periods explicitly, discusses acquisitions, and provides management commentary on performance and outlook. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full financial report rather than a brief announcement or a certification. The document is not a transcript, proxy, or governance report, but a full annual financial performance report. Therefore, it fits the definition of an Annual Report (10-K equivalent). FY 2020
2020-06-22 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.